Cardiology Today Current Issue

The following articles appeared in the print edition of Cardiology Today.

Table of Contents

• Role of PCSK9 inhibition continues to evolve
• Global Cardio-Oncology Summit brings together cardiologists, oncologists Michael Fradley, MD; Javid J. Moslehi, MD
• New physical activity guidelines encourage movement ‘anytime, anywhere’
• EMPA-REG: Empagliflozin can add 4 years to life expectancy in diabetes with CVD
• Higher dairy intake may lower CVD, mortality risks
• SGLT1 variants tied to lower risk for HF, diabetes, obesity, death
• SGLT2 inhibitor prescription rates low among cardiologists
• Sleep duration related to stroke risk, varies by race
• CIRT: Methotrexate fails to prevent atherosclerotic events
• Computerized alert system confers more anticoagulation use, better outcomes in AF
• DECLARE-TIMI 58: Dapagliflozin reduces HF hospitalization in type 2 diabetes
• Electronic decision support system fails to improve outcomes in hypertension, diabetes
• PIONEER-HF: Sacubitril/valsartan superior to enalapril in acute decompensated HF
• REDUCE-IT: Icosapent ethyl reduces ischemic events in high-risk patients
• REGROUP: Event rate similar in open vs. endoscopic vein grafting for CABG
• VITAL: Mixed findings for vitamin D, omega-3s in CVD, cancer prevention
• AF-ALERT
• CIRT
• CIRT
• DECLARE-TIMI 58
• EWTOPIA75
• FREEDOM Follow-On
• NODE-1
• PIONEER-HF
• VITAL